Literature DB >> 1936251

Remarkably enhanced expression of the type II hexokinase in rat hepatoma cell line AH130.

Y Shinohara1, J Ichihara, H Terada.   

Abstract

Expression of mRNAs encoding hexokinase isozymes was studied in various cells such as rat brain, liver, skeletal muscle, kidney and heart, and the rat hepatoma cell line AH130 by Northern blotting. High specific expression of type II hexokinase was observed only with AH130 cells. In contrast, specific expression of type I hexokinase was detected in energy-requiring normal tissue cells such as brain and heart. These results suggest that the expression of hexokinase isozyme in the tumor cells is different from that in normal cells.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1936251     DOI： 10.1016/0014-5793(91)81102-e

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  13 in total

1.  Reduced survival of patients with hepatocellular carcinoma expressing hexokinase II.

Authors:  Lei Gong; Zhuqingqing Cui; Pengcheng Chen; Hui Han; Jirun Peng; Xisheng Leng
Journal:  Med Oncol       Date:  2011-01-30       Impact factor: 3.064

Review 2.  Impact of smoking status on the biological behavior of lung cancer.

Authors:  Ichiro Yoshino; Yoshihiko Maehara
Journal:  Surg Today       Date:  2007-08-27       Impact factor: 2.549

3.  Hexokinase II in CD133+ and CD133- hepatoma BEL-7402 Cells.

Authors:  Lei Gong; Zhuqingqing Cui; Xin Yu; Yuhua Wei; Jirun Peng; Xisheng Leng
Journal:  Pathol Oncol Res       Date:  2011-09-10       Impact factor: 3.201

4.  Microheterogeneity of cytosolic and membrane-bound hexokinase II in Morris hepatoma 3924A.

Authors:  A Rempel; P Bannasch; D Mayer
Journal:  Biochem J       Date:  1994-10-01       Impact factor: 3.857

5.  Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate.

Authors:  Ayako Nakano; Hirokazu Miki; Shingen Nakamura; Takeshi Harada; Asuka Oda; Hiroe Amou; Shiro Fujii; Kumiko Kagawa; Kyoko Takeuchi; Shuji Ozaki; Toshio Matsumoto; Masahiro Abe
Journal:  J Bioenerg Biomembr       Date:  2012-02       Impact factor: 2.945

Review 6.  Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase.

Authors:  S P Mathupala; A Rempel; P L Pedersen
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

7.  Expressions of hypoxia-inducible factor-1α and hexokinase-II in gastric adenocarcinoma: the impact on prognosis and correlation to clinicopathologic features.

Authors:  Miao-Zhen Qiu; Bing Han; Hui-Yan Luo; Zhi-Wei Zhou; Zhi-Qiang Wang; Feng-Hua Wang; Yu-Hong Li; Rui-Hua Xu
Journal:  Tumour Biol       Date:  2010-09-16

8.  Hepatocyte nuclear factor 1α-inactivated hepatocellular adenomas exhibit high (18)F-fludeoxyglucose uptake associated with glucose-6-phosphate transporter inactivation.

Authors:  Kumi Ozaki; Kenichi Harada; Noboru Terayama; Osamu Matsui; Satoshi Saitoh; Yoshito Tomimaru; Takeshi Fujii; Toshifumi Gabata
Journal:  Br J Radiol       Date:  2016-05-20       Impact factor: 3.039

9.  The antitumor effect and hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: in vivo investigation of intraarterial administration in a rabbit VX2 hepatoma model.

Authors:  Hwan Jun Jae; Jin Wook Chung; Hee Sun Park; Min Jong Lee; Ki Chang Lee; Hyo-Cheol Kim; Jung Hwan Yoon; Hesson Chung; Jae Hyung Park
Journal:  Korean J Radiol       Date:  2009 Nov-Dec       Impact factor: 3.500

Review 10.  The Warburg effect and its cancer therapeutic implications.

Authors:  Zhao Chen; Weiqin Lu; Celia Garcia-Prieto; Peng Huang
Journal:  J Bioenerg Biomembr       Date:  2007-06       Impact factor: 2.945
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.